Wireless, catheter-free Glean Urodynamics System, designed to revolutionize quantitative urological testing, utilizes exclusive licensing from Cleveland Clinic
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, announced today the launch of the company with $4 million in seed financing from Academy Investor Network, Fred Moll, and several other prominent angel investors. Bright Uro was also awarded a $2 million Phase II SBIR grant from the National Institutes of Health (NIH).
The company has obtained an exclusive licensing agreement from Cleveland Clinic for technology Cleveland Clinic developed in collaboration with the Department of Veterans Affairs, Case Western Reserve University, and Parker Hannifin Corporation, which Bright Uro will use in its investigational Glean Urodynamics System.
Urodynamic tests are completed for patients with urine leaks, bladder emptying complications, urine flow issues, and other lower urinary tract symptoms (LUTS) to measure how well the bladder, sphincters, and urethra hold and release urine. Millions of Americans experience LUTS associated with overactive bladder (OAB), benign prostatic hyperplasia (BPH), and more.1,2 However, urodynamics are often underused due to cost, inaccuracy, and patient discomfort.